References
Scheen AJ, Lefèbvre PJ. Oral antidiabetic agents: a guide to selection. Drugs 1998 Feb; 55(2): 225–36
Wills C, Page S. Oral antidiabetic drugs: role in the management of type 2 diabetes. Prescriber 1998 May 19; 79, 82–3
British National Formulary No. 35. London: The Pharmaceutical Press, 1998 Mar: 303–6
PDR Generics. 4th ed. Montvale (NJ): Medical Economics, 1998: 2752–6
Scheen AJ, Lefèbvre PJ. Pathophysiology of type 2 diabetes. In: Kuhlmann J, Puls W, editors. Handbook of experimental pharmacology: oral antidiabetics. Berlin: Springer Verlag, 1995: 7–42
Brown A. Diabetes mellitus (3): management of non-insulin-dependent diabetes mellitus. Pharm J 1998 Jun 20; 260: 905–7
Sirtori CR, Pasik C. Re-evaluation of a biguanide, metformin: mechanism of action and tolerability. Pharmacol Res 1994; 30: 187–228
Henry RR. Thiazolidinediones. Endocrinol Metab Clin North Am 1997; 26: 553–73
Riddle MC. Tactics for type II diabetes. Endocrinol Metab Clin North Am 1997; 26: 659–77
United Kingdom Prospective Diabetes Study Group. UK Prospective Diabetes Study 13: relative efficacy of randomly allocated diet, sulfonylurea, insulin or metformin in patients with newly diagnosed non-insulin-dependent diabetes followed for three years. BMJ 1995; 310: 83–8
United Kingdom Prospective Diabetes Study Group. UK Prospective Diabetes Study 16: Overview of 6 years’ therapy of type II diabetes: a progressive disease. Diabetes 1995; 44: 1249–58
Rights and permissions
About this article
Cite this article
New oral antihyperglycaemic agents expand armamentarium in the battle against type 2 diabetes mellitus. Drugs Ther. Perspect 12, 6–10 (1998). https://doi.org/10.2165/00042310-199812070-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00042310-199812070-00002